(888) 552-6760 SCHEDULE A CONSULTATION
Clinical-Trials

Clinical trials

Search our clinical trials

Cancer Treatment Centers of America® (CTCA) is committed to providing new and innovative treatments for our cancer patients whenever possible. This includes enrolling qualified patients in carefully selected clinical trials for cancer. Clinical trials are a key testing ground for determining the effectiveness and safety of new treatments and drugs for cancer and other diseases. Our doctors may recommend that cancer patients enroll in cancer clinical trials if they meet specific criteria. Cancer trials may offer patients access to treatment options that would otherwise be unavailable to them. Talk to your doctor about whether a cancer trial is a good option for you and ask about the risks and various requirements involved. Use the tool below to find a CTCA® clinical trial for your cancer type.

Filters

42 Clinical Trials

This phase III trial studies how well the combination of pembrolizumab, paclitaxel and carboplatin works compared with paclitaxel and carboplatin alone in treating patients with endometrial cancer that is stage III or IV, or has come back.

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

The primary objective of this study for the safety run-in cohorts of the study is to evaluate the safety, tolerability, and recommended Phase 2 dose (RP2D) of magrolimab in combination with nab-paclitaxel or paclitaxel (safety run-in cohort 1), and sacituzumab govitecan (safety run-in cohort 2) in metastatic triple-negative breast cancer (mTNBC).

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

A phase 2 study of magrolimab combination therapy in patients with head and neck squamous cell carcinoma

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

This is an open-label, multicenter, randomized, parallel groups study of GPS vs. best available treatment (BAT) in patients with AML in second complete remission (CR2) or in second complete remission with incomplete platelet recovery (CRp2).

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

This phase II/III Lung-MAP trial studies how well immunotherapy treatment with N-803 (ALT-803) and pembrolizumab working in treating patients with non-small cell lung cancer that has spread to other places in the body (advanced).

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

This is a global phase 2, multi-center, single-arm, open label study of taletrectinib in patients of NSCLC harboring with ROS1 fusion gene.

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

ATLAS-IT-05 is an open-label, single-arm study in patients with advanced melanoma accessible for injections (cutaneous, subcutaneous, lymph node, or intramuscular tumors) and who have either exhausted treatment options or are not eligible for, suitable for, or willing to undergo such treatments.

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

This study is a phase 1b/2, multi-center, open-label study in which patients with activating mutations in the RAS pathway (phase 1b) and patients with NRAS-mutated melanoma (phase 2) will be treated with a combination of oral OKI-179 combined with the MEK inhibitor binimetinib.

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

This study is a randomized, double-blind, multi-center phase 3 clinical study to compare the efficacy and safety of penpulimab combined with chemotherapy and placebo combined with chemotherapy in the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma.

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

This is a phase 3 study of AVB-S6-500 in combination with paclitaxel (Pac) in patients with platinum resistant recurrent ovarian cancer. This is a randomized, double-blind, placebo-controlled study to compare efficacy and tolerability of AVB-S6-500 in combination with Pac versus placebo plus Pac.